18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

19 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-18

Study Completion Date

2024-11-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I trial studies the ability and amount of fluciclovine positron emission tomography (PET) imaging needed to recognize tumors that have come back (recurrence) after brain injury from radiation therapy (radionecrosis) in patients with intracranial disease that has spread to other places in the body (metastatic). F-18 fluciclovine is a radiotracer that works by accumulating in tumor cells, making it easier to detect tumors. The results of this study may also help investigators understand all the ways that F-18 fluciclovine may affect patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

NCT06055790

Brain Metastases

RECRUITING PHASE2

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

NCT04410133

Brain Metastases

COMPLETED PHASE3

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

NCT04689048

Brain Metastases, Adult Brain Metastases Brain Cancer

RECRUITING PHASE1

18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis

NCT03930173

Secondary Malignant Neoplasm of Brain and Cerebral Meninges

COMPLETED EARLY_PHASE1

18F-FLUC PET/MR in Patients With Brain Mets

NCT06159335

Brain Metastasis Radiation Therapy Immunotherapy, Active

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To determine the static fluciclovine F18 (fluciclovine) PET imaging tumor-to-background ratios (TBRmax; TBRmean) which distinguish true tumor recurrence from radionecrosis in patients with intracranial metastatic disease previously treated with radiation therapy, and magnetic resonance imaging (MRI) findings suggesting recurrent disease, using histopathology as proof of disease.

SECONDARY OBJECTIVES:

I. To determine static fluciclovine PET standardized uptake value (SUV)peak, SUVmean values and metabolic tumor volumes (MTV) which distinguish true tumor recurrence from radionecrosis in patients with MRI findings suggesting recurrent disease, using serial MRI as a surrogate marker of disease.

II. To determine early dynamic fluciclovine PET time activity curve values which distinguish true tumor recurrence from radionecrosis in patients with MRI findings suggesting recurrent disease, using histopathology or serial MRI as a marker of disease.

III. To correlate the determined static fluciclovine PET SUVpeak, SUVmean, TBRmax, TBRmean, and MTV values with progression free survival.

IV. In patients with true tumor progression, SUV values will be correlated with Ki67 staining on final pathology.

OUTLINE:

Patients receive fluciclovine intravenously (IV) and undergo brain dynamic PET/MRI imaging over 50 minutes.

After completion of study, patients are followed up every 3 months for up to 1 year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Intracranial Malignant Neoplasm Recurrent Intracranial Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic (18F-fluciclovine, PET/MRI imaging)

Patients receive fluciclovine IV and undergo brain dynamic PET/MRI imaging over 50 minutes.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography

Intervention Type RADIATION

Undergo PET-MRI imaging

Fluciclovine F18

Intervention Type OTHER

Given IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography

Undergo PET-MRI imaging

Intervention Type RADIATION

Fluciclovine F18

Given IV

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DCE-MRI with PET DCE-MRI/PET (18F)Fluciclovine (18F)GE-148 18F-Fluciclovine [18F]FACBC Anti-(18f)FABC Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid Anti-[18F] FACBC Axumin Fluciclovine (18F) FLUCICLOVINE F-18 GE-148 (18F) GE-148 F-18

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical evidence of intracranial metastatic disease which underwent radiation and who presents with MRI findings suspicious for recurrent disease and/or radionecrosis (namely the 'index lesion')

Exclusion Criteria

* Contraindication to contrast enhanced MRI
* Females of child-bearing potential who are pregnant or lactating or who are not using adequate contraception (surgical, hormonal or double barrier, i.e. condom and diaphragm)
* Inability to lie still for 50 minutes during fluciclovine PET-MRI imaging
* Inability or refusal to consent
* Allergy or anaphylaxis to any of the reagents used in this study
* Inability or unwillingness to return for required visits and follow-up exams

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No